Clearmind Medicine (Clearmind Medicine) Retained Earnings : $-20.14 Mil (As of Jan. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Clearmind Medicine Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Clearmind Medicine's retained earnings for the quarter that ended in Jan. 2024 was $-20.14 Mil.

Clearmind Medicine's quarterly retained earnings declined from Jul. 2023 ($-11.09 Mil) to Oct. 2023 ($-13.57 Mil) and declined from Oct. 2023 ($-13.57 Mil) to Jan. 2024 ($-20.14 Mil).

Clearmind Medicine's annual retained earnings declined from Oct. 2021 ($-3.58 Mil) to Oct. 2022 ($-7.46 Mil) and declined from Oct. 2022 ($-7.46 Mil) to Oct. 2023 ($-13.57 Mil).

Clearmind Medicine Retained Earnings Historical Data

The historical data trend for Clearmind Medicine's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clearmind Medicine Retained Earnings Chart

Clearmind Medicine Annual Data

Trend

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Retained Earnings

Get a 7-Day Free Trial

-0.23

-0.41

-3.58

-7.46

-13.57

Clearmind Medicine Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Retained Earnings	Get a 7-Day Free Trial															-12.19	-10.34	-11.09	-13.57	-20.14

Clearmind Medicine Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Clearmind Medicine (NAS:CMND) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Clearmind Medicine (Clearmind Medicine) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearmind Medicine Inc (NAS:CMND) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

CWY0:Germany CWY0:Germany CMND:Canada

Address

101-1220 West 6th Avenue, Vancouver, BC, CAN, V6H 1A5

Website

https://www.clearmindmedicine.com

Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.